Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769412 · ClinicalTrials.gov registry record
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 550,000
- Enrollment target
NCT06769412: Completed study, sponsored by Regeneron Pharmaceuticals.
NCT06769412 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 550,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06769412 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 550,000 participants
- Enrollment target
Study Summary
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classification of Diseases, tenth revision, Clinical Modification (ICD-10-CM) codes and to identify RV with occlusion.
Interventions
- DRUG aflibercept 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550,000 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2025-09-01 |
What the finished NCT06769412 record still lists
NCT06769412 is an observational study that tracks outcomes without assigning an intervention. Its 550,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which aflibercept 2 mg is the first listed.
NCT06769412 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06769412 about?
NCT06769412 is a clinical study titled "A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)". This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classifi...
What is the current status of trial NCT06769412?
This trial is currently completed. The enrollment target is 550,000 participants. The study started on 2025-07-01. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT06769412?
The interventions under investigation include: aflibercept 2 mg (DRUG).
Who is sponsoring clinical trial NCT06769412?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI